CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $1.01B, above the global median of $520.53M
- FinancialsAltman Z-Score 2.87: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
5.90%
Annual Rate
MXN 0.80Paid quarterly
Payout Ratio
48.1%Sustainable
Payback Period
17.1 yr
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.26BMXN784.42M · vs all stocks (USD)
Trailing P/E
8.09xRevenue (TTM)
17.05BMXN1.01B · vs all stocks (USD)
Profit Margin
9.56%Beta
0.1350xvs all stocks
52-Week Change
-38.95%vs all stocks
Forward Annual Dividend Yield
5.90%vs all stocks
Market Capitalization
13.26BMXN784.42M · vs all stocks (USD)
Enterprise Value
18.53BMXN1.10B · vs all stocks (USD)
Trailing P/E
8.09xForward P/E
6.30xPEG Ratio
1.59xPrice to Sales (TTM)
0.7703xPrice to Book (MRQ)
1.12xEnterprise to Revenue
1.09xEnterprise to EBITDA
4.76xGross Margin
64.56%Profit Margin
9.56%Operating Margin
19.95%Return on Assets (TTM)
9.10%Return on Equity (TTM)
14.16%Revenue (TTM)
17.05BMXN1.01B · vs all stocks (USD)
Revenue per Share (TTM)
17.40MXNUpdated Aug 21, 2026Quarterly Revenue Growth
-6.00%Gross Profit (TTM)
10.78BMXN637.88M · vs all stocks (USD)
EBITDA (TTM)
3.86BMXN228.42M · vs all stocks (USD)
Net Income (TTM)
1.63BMXN96.40M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
5.50%Operating Cash Flow (TTM)
1.85BMXN109.45M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
438.72MMXN25.96M · vs all stocks (USD)
Forward Annual Dividend Rate
0.8000MXNUpdated Aug 21, 2026Forward Annual Dividend Yield
5.90%vs all stocks
Trailing Annual Dividend Rate
0.8000MXNUpdated Aug 21, 2026Trailing Annual Dividend Yield
5.90%vs all stocks
Payout Ratio
48.13%Revenue
17.54BMXNFY2025 · Dec 31, 2025Cost of Goods Sold
6.52BMXNFY2025 · Dec 31, 2025Gross Profit
11.02BMXNFY2025 · Dec 31, 2025Operating Income
3.73BMXN220.68M · vs all stocks (USD)
Pre-tax Income
2.43BMXNFY2025 · Dec 31, 2025Income Tax Expense
826.24MMXNFY2025 · Dec 31, 2025Net Income
1.61BMXNFY2025 · Dec 31, 2025EBIT
3.23BMXNFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.86BMXNFY2025 · Dec 31, 2025Selling, General & Administrative
6.95BMXNFY2025 · Dec 31, 2025Non-operating Interest Income
114.02MMXNFY2025 · Dec 31, 2025Non-operating Interest Expense
796.70MMXNFY2025 · Dec 31, 2025EPS (Basic)
1.65MXNFY2025 · Dec 31, 2025EPS (Diluted)
1.65MXNFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.61BMXNFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00MXNFY2025 · Dec 31, 2025Operating Cash Flow
1.75BMXNFY2025 · Dec 31, 2025Free Cash Flow
1.74BMXNFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.05BMXNFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.61BMXNFY2025 · Dec 31, 2025Other Non-cash Items
942.80MMXNFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-602.36MMXNFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-196.24MMXNFY2025 · Dec 31, 2025Capital Expenditures
10.80MMXNFY2025 · Dec 31, 2025Purchase of Investments
-34.27MMXNFY2025 · Dec 31, 2025Other Investing Activity
-170.88MMXNFY2025 · Dec 31, 2025Net Investing Cash Flow
-194.35MMXNFY2025 · Dec 31, 2025Long-term Debt Issuance
5.03BMXNFY2025 · Dec 31, 2025Long-term Debt Payments
-3.83BMXNFY2025 · Dec 31, 2025Common Dividends Paid
-781.77MMXNFY2025 · Dec 31, 2025Net Financing Cash Flow
419.21MMXNFY2025 · Dec 31, 2025Shares Outstanding
977.75MSharesUpdated Aug 21, 2026Float Shares
672.56MSharesUpdated Aug 21, 2026% Held by Insiders
31.05%vs all stocks
% Held by Institutions
33.68%vs all stocks
Total Cash (MRQ)
2.41BMXN142.73M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.47MXNUpdated Aug 21, 2026Total Debt (MRQ)
7.85BMXN464.38M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6665xCurrent Ratio (MRQ)
1.41xBook Value per Share (MRQ)
12.01MXNUpdated Aug 21, 2026Total Assets
23.83BMXN1.41B · vs all stocks (USD)
Total Current Assets
12.84BMXNFY2025 · Dec 31, 2025Total Liabilities
12.72BMXNFY2025 · Dec 31, 2025Total Non-current Assets
11.00BMXNFY2025 · Dec 31, 2025Total Non-current Liabilities
5.49BMXNFY2025 · Dec 31, 2025Total Current Liabilities
7.23BMXNFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.07BMXNFY2025 · Dec 31, 2025Accounts Receivable
4.50BMXNFY2025 · Dec 31, 2025Inventory
1.84BMXNFY2025 · Dec 31, 2025Accounts Payable
1.58BMXNFY2025 · Dec 31, 2025Short-term Debt
2.80BMXNFY2025 · Dec 31, 2025Other Current Liabilities
2.60BMXNFY2025 · Dec 31, 2025Long-term Debt
4.77BMXNFY2025 · Dec 31, 2025Other Non-current Liabilities
720.36MMXNFY2025 · Dec 31, 2025Common Stock (Book)
1.83BMXNFY2025 · Dec 31, 2025Retained Earnings
12.22BMXNFY2025 · Dec 31, 2025Total Shareholders' Equity
11.11BMXN657.40M · vs all stocks (USD)
Treasury Stock
1.85BMXNFY2025 · Dec 31, 202552-Week Low
13.25MXNUpdated Aug 21, 202652-Week High
23.20MXNUpdated Aug 21, 202652-Week Change
-38.95%vs all stocks
Beta
0.1350xvs all stocks
50-Day MA
14.64MXNUpdated Aug 21, 2026200-Day MA
16.74MXNUpdated Aug 21, 2026Avg 10-Day Volume
1.88MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.94MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.66MXNUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.87: safe zoneNotable
Altman Z-Score: 2.87
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $1.01B, above the global median of $520.53MNotable
Revenue (USD): 1,008,512,853.398Global Median: 520,528,949.311
Levered free cash flow is $25.96M, above the global median of $16.24MNotable
Levered free cash flow (USD): 25,956,547.461Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vireo Growth Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk